Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01815333 · ClinicalTrials.gov registry record · NA
Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging
A NA study of Cancer of Lymph Node, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01815333 is a NA study of Cancer of Lymph Node that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01815333, a NA study of Cancer of Lymph Node, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if the drug Feraheme ® (ferumoxytole) helps researchers most clearly to "see" cancerous lymph nodes on an MRI scan. Researchers also want to learn if ferumoxytole may be used in liver imaging. Ferumoxytole is designed to deliver iron to treat iron-deficiency anemia (low red blood cell counts) in patients with chronic kidney disease. In this study, it will be used as an MRI contrast. Contrasts are used by doctors in order to see MRI images more clearly.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- DRUG Feraheme
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-07-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01815333
The ClinicalTrials.gov registry entry for NCT01815333 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer of Lymph Node appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT01815333 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01815333 about?
NCT01815333 is a clinical study titled "Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging". The goal of this clinical research study is to learn if the drug Feraheme ® (ferumoxytole) helps researchers most clearly to "see" cancerous lymph nodes on an MRI scan. Researchers also want to learn if ferumoxytole may be used in liver imaging. Ferumoxytole is designed to deliver iron to treat iro...
What is the current status of trial NCT01815333?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2013-07. Estimated completion is 2019-07-25.
What conditions does trial NCT01815333 study?
This clinical trial studies the following conditions: Cancer of Lymph Node.
What interventions are being tested in trial NCT01815333?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Feraheme (DRUG).
Who is sponsoring clinical trial NCT01815333?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01815333 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.